Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA Timetable Unclear, But Negotiations Will Begin With Lots Of Agreement - Except For Mylan

This article was originally published in The Pink Sheet Daily

Executive Summary

Coalition and GPhA expect to be on the same page at FDA public meeting, but Mylan proposes alternative user fee structure based on establishment fees.

Related Content

GDUFA Talks: FDA Reminds Industry The Program Is Generic-Only
GPhA Seeks New Driver As Outgoing VP Johnston Continues To Ford Across User Fee Stream
Generic User Fees Have Four-Month Negotiating Window As Differences Narrow
Generic User Fees: FDA Reaches Out To More Trade Groups; Plan Could Mix Inspection and Application Fees
Establishment Fees Protect American Manufacturing, Mylan Argues In User Fee Proposal
Regulatory And Policy News, In Brief
ANDA Deficiencies Persist Despite QbR; Reviews to Focus More on Excipients
FDA Must Maintain Oversight Role In PMI Development, Groups Urge
Generic User Fee Negotiations: Should Different Kinds Of ANDAs Pay More?
ANDA User Fees: Industry Takes Holistic Approach, Wants Whole New Office





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts